Pacira Pharmaceuticals says data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) used in peripheral nerve blocks is comparably as safe as placebo and bupivacaine hydrochloride, ...
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
NEW YORK--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from EXCLAIM, its Phase 4 prospective, observational study to assess the use of EXPAREL® (bupivacaine ...
TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX),, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
EXPAREL (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia via ...
Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel ...
In a recent clinical trial, Pacira Pharmaceuticals found its drug EXPAREL reduced cumulative pain scores through 72 hours better than bupivacaine HCI. The company published results from nine clinical ...
TAMPA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NSDQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
According to the American College of Surgeons, 15 million Americans undergo surgery each year. Despite this high frequency and the significant impact these procedures can have on patients, no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results